# Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

> **NCT02220673** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 61 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BHT 0.1%
- **DRUG:** BHT 0.5%
- **DRUG:** Placebo for RMT-B
- **DRUG:** Placebo for HFA-MDI

## Key facts

- **NCT ID:** NCT02220673
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-05
- **Final completion:** —
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220673, "Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02220673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*